Movatterモバイル変換

Milameline

From Wikipedia, the free encyclopedia

Chemical compound

Pharmaceutical compound

Milameline
Clinical data

ATC code	None
Identifiers
IUPAC name (E)-N-methoxy-1-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)methanimine
CAS Number	139886-32-1
PubChemCID	9571002
IUPHAR/BPS	301
ChemSpider	7845468
UNII	R9X77R42FN
CompTox Dashboard(EPA)	DTXSID401028867
ECHA InfoCard	100.220.595
Chemical and physical data
Formula	C₈H₁₄N₂O
Molar mass	154.213 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES N(/OC)=C\C1=C\CCN(C)C1

Milameline (CI-979,PD-129,409,RU-35,926) is anon-selective muscarinic acetylcholine receptor partial agonist withcognition-acting properties that was being investigated for the treatment ofAlzheimer's disease, but produced poor results inclinical trials and was subsequently discontinued.^[1]

Changing theO-methyl aldoxime to anO-propargyl oxime instead gives a separate molecule calledRU 35986.^[2]

^Sedman AJ, Bockbrader H, Schwarz RD (1995). "Preclinical and phase 1 clinical characterization of CI-979/RU35926, a novel muscarinic agonist for the treatment of Alzheimer's disease".Life Sciences.56 (11–12):877–882.doi:10.1016/0024-3205(95)00023-Y.PMID 10188788.
^Broadley KJ, Kelly DR (2001)."Muscarinic Receptor Agonists and Antagonists".Molecules.6 (3):142–193.doi:10.3390/60300142.ISSN 1420-3049.PMC 6236374.

v t e Psychoanaleptics: Anti-dementia agents (ATC codeN06D and others)
AChE inhibitor medications	Benzgalantamine Donepezil (+memantine) Galantamine Ipidacrine Rivastigmine Tacrine
Other medications	Aducanumab Bifemelane Donanemab Ginkgo folium Lecanemab Meclofenoxate (centrophenoxine) Memantine (+donepezil) Nicergoline
ExperimentalBACE inhibitors	Lanabecestat Verubecestat